TORONTO, June 21, 2018 /PRNewswire/ --
Eyecarrot Innovations Corp ("Eyecarrot" or the "Company") (TSX-V: EYC) (OTCQB:EYCCF) is pleased to announce that it has initiated delivery of the Binovi Touch Saccadic Fixator to some of the top Academic Institutions in North America. The company is now working with leading vision researchers from
"Our company has moved from conceptual design, to now fulfilling shipments to World Class Institutions in the United States in under 24 months. We can now accelerate further expansion into the market and extend the reach of our Binovi Touch globally," stated CEO Adam Cegielski.
The company has now shipped 100 units of the Binovi Touch vision performance hardware since release 2 months ago. This represents a year-over-year-growth in unit sales of over 500% since 2017. The company continues to receive significant interest and increase in sales while showcasing its hardware at the 48th Annual College of Optometrists in Vision Development Meeting.
"Recent feedback from the market has emphasized the utility of the Binovi Touch, as our customers are using the product every day and on every patient. We are pleased with this increase in demand, and overall reception of our platform. Optometrists are appreciating the expanded feature sets, their therapy teams are embracing the modernization, and their patients are thrilled with overall performance. Our next steps are working towards increasing production and carrying inventory of our flagship product with the intent of replacing the 5,000 analog models currently in the market," commented CEO Adam Cegielski.
Key differentiating features of the device can be found below:
Eyecarrot's Binovi platform is an innovative healthcare technology solution that integrates software, hardware, data and expert knowledge. Binovi helps optometrists treat vision issues with in-office therapy as well as doctor led home based activities to better serve and increase the patient's experience and their therapy needs. The goal is to help transform vision performance for the 1 in 4 people worldwide that suffer from vision-related issues going beyond visual acuity. The company is transforming how vision healthcare services are integrated, while addressing key challenges in the health system.
On behalf of the Board of Directors
President | CEO
Forward looking information
Certain statements contained in this news release constitute "forward-looking information" as such term is used in applicable Canadian securities laws. Forward-looking information is based on plans, expectations, and estimates of management at the date the information is provided and is subject to certain factors and assumptions, including, that the Company's financial condition and development plans do not change as a result of unforeseen events and that the Company obtains regulatory approval. Forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause plans, estimates and actual results to vary materially from those projected in such forward-looking information. Factors that could cause the forward-looking information in this news release to change or to be inaccurate include, but are not limited to, the risk that any of the assumptions referred to prove not to be valid or reliable, that occurrences such as those referred to above are realized and result in delays, or cessation in planned work, that the Company's financial condition and development plans change, and delays in regulatory approval, as well as the other risks and uncertainties applicable to the Company as set forth in the Company's continuous disclosure filings filed under the Company's profile at http://www.sedar.com . The Company undertakes no obligation to update these forward-looking statements, other than as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact: T: +(416)-943-6271 / +1-855-416-7158 email@example.com
SOURCE Eyecarrot Innovations Corp
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All